Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 77

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 77
---
 New York, NY 10018. The phone
number and facsimile number for Equity Stock Transfer are (212) 575-5757 and (347) 584-3644, respectively. Additional information about
Equity Stock Transfer can be found on its website at www.equitystock.com.

Dividend Policy

We have never paid any cash dividends on our
common stock. We anticipate that we will retain funds and future earnings to support operations and to finance the growth and development
of our business. Therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination to pay dividends
will be at the discretion of our Board and will depend on our financial condition, results of operations, capital requirements, and other
factors that our Board deems relevant. In addition, the terms of any future debt or credit financings may preclude us from paying dividends.

Unregistered Sales of Equity Securities

Common Stock

    ●
    On July 22, 2024 and July 26,
                                    2024, we issued 8,000 and 6,667 shares of common stock to Knight, respectively, upon conversion of
                                    1,291 and 1,032 shares of Series A Preferred Stock, respectively, at the conversion price detailed
                                    in Note 6 to the accompanying consolidated financial statements.

    ●
    From October 2024 to January 2025,
                                    we issued an aggregate of 579,711 shares of common stock upon the exercise of pre-funded warrants
                                    issued to investors in the September 2024 private placement.

The issuances of shares of common stock listed
above were deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that
the issuance of securities did not involve a public offering.

41

Warrants

On September 4, 2024, we issued 579,711 pre-funded
warrants, 579,711 Series A Warrants and 579,711 Series B Warrants to investors in a private offering. The Pre-Funded Warrants are exercisable
immediately upon issuance and expire when exercised in full at an exercise price of $0.005 per share. The Series A Warrants and Series
B Warrants have an exercise price of $6.90 per share and were exercisable beginning on the effective date of stockholder approval of
the issuance of the shares of Common Stock (the “Stockholder Approval”), which was